The Gut Microbiome's Influence on Incretins and Impact on Blood Glucose Control

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2025 Jan 8

PMID 39767626

Authors

Ajay S Dulai

Mildred Min

Raja K Sivamani

Affiliations

Soon will be listed here.

Abstract

Obesity and type 2 diabetes mellitus (T2DM) have been increasing in prevalence, causing complications and strain on our healthcare systems. Notably, gut dysbiosis is implicated as a contributing factor in obesity, T2DM, and chronic inflammatory diseases. A pharmacology exists which modulates the incretin pathway to improve glucose control; this has proven to be beneficial in patients with obesity and T2DM. However, it is unclear how the gut microbiome may regulate insulin resistance, glucose control, and metabolic health. In this narrative review, we aim to discuss how the gut microbiome can modulate incretin pathways and related mechanisms to control glucose. To investigate this, Google Scholar and PubMed databases were searched using key terms and phrases related to the microbiome and its effects on insulin and glucose control. Emerging research has shown that several bacteria, such as and MN-Gup, have GLP-1-agonistic properties capable of reducing hyperglycemia. While more human research is needed to prove clinical benefit and identify long-term implications on health, the usage of pre-, pro-, and postbiotics has the potential to improve glucose control.

References

Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi S . Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods. 2019; 8(3). PMC: 6463098. DOI: 10.3390/foods8030092. View

Nauck M, Muller T . Incretin hormones and type 2 diabetes. Diabetologia. 2023; 66(10):1780-1795. PMC: 10474001. DOI: 10.1007/s00125-023-05956-x. View

Zhang C, Fang B, Zhang N, Zhang Q, Niu T, Zhao L . The Effect of subsp. MN-Gup on Glucose Metabolism, Gut Microbiota, and Their Metabolites in Type 2 Diabetic Mice. Nutrients. 2024; 16(11). PMC: 11174421. DOI: 10.3390/nu16111691. View

Cheng Z, Chen J, Zhang Y, Li X, Zhang N, Liu F . In Vitro Hypoglycemic Activities of and Strains from Healthy Children's Sources and Their Effect on Stimulating GLP-1 Secretion in STC-1 Cells. Foods. 2024; 13(4). PMC: 10887728. DOI: 10.3390/foods13040519. View

Everard A, Lazarevic V, Derrien M, Girard M, Muccioli G, Muccioli G . Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes. 2011; 60(11):2775-86. PMC: 3198091. DOI: 10.2337/db11-0227. View

Kurihara Y, Akahane Y, Nakayama T, Suzuki K . [Measuring the areas of structural components in cephalometric radiographs: designating the areas]. Nichidai Koko Kagaku. 1986; 12(4):447-53. View

Gasbjerg L, Bergmann N, Stensen S, Christensen M, Rosenkilde M, Holst J . Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. 2019; 125:170183. DOI: 10.1016/j.peptides.2019.170183. View

Lv W, Wang X, Xu Q, Lu W . Mechanisms and Characteristics of Sulfonylureas and Glinides. Curr Top Med Chem. 2019; 20(1):37-56. DOI: 10.2174/1568026620666191224141617. View

Seino Y, Fukushima M, Yabe D . GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig. 2014; 1(1-2):8-23. PMC: 4020673. DOI: 10.1111/j.2040-1124.2010.00022.x. View

10.

Iatcu C, Steen A, Covasa M . Gut Microbiota and Complications of Type-2 Diabetes. Nutrients. 2022; 14(1). PMC: 8747253. DOI: 10.3390/nu14010166. View

11.

Shaefer Jr C, Kushner P, Aguilar R . User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015; 127(8):818-26. DOI: 10.1080/00325481.2015.1090295. View

12.

Larsen M, Torekov S . Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?. J Diabetes Res. 2017; 2017:7583506. PMC: 5610892. DOI: 10.1155/2017/7583506. View

13.

Chambers E, Byrne C, Morrison D, Murphy K, Preston T, Tedford C . Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised.... Gut. 2019; 68(8):1430-1438. PMC: 6691855. DOI: 10.1136/gutjnl-2019-318424. View

14.

Le Guern R, Stabler S, Gosset P, Pichavant M, Grandjean T, Faure E . Colonization resistance against multi-drug-resistant bacteria: a narrative review. J Hosp Infect. 2021; 118:48-58. DOI: 10.1016/j.jhin.2021.09.001. View

15.

Dubnau D, Blokesch M . Mechanisms of DNA Uptake by Naturally Competent Bacteria. Annu Rev Genet. 2019; 53:217-237. DOI: 10.1146/annurev-genet-112618-043641. View

16.

Gomes A, Hoffmann C, Mota J . The human gut microbiota: Metabolism and perspective in obesity. Gut Microbes. 2018; 9(4):308-325. PMC: 6219651. DOI: 10.1080/19490976.2018.1465157. View

17.

Gu L, Fu R, Hong J, Ni H, Yu K, Lou H . Effects of Intermittent Fasting in Human Compared to a Non-intervention Diet and Caloric Restriction: A Meta-Analysis of Randomized Controlled Trials. Front Nutr. 2022; 9:871682. PMC: 9108547. DOI: 10.3389/fnut.2022.871682. View

18.

Di W, Zhang Y, Zhang X, Han L, Zhao L, Hao Y . Heterologous expression of P9 from Akkermansia muciniphila increases the GLP-1 secretion of intestinal L cells. World J Microbiol Biotechnol. 2024; 40(7):199. DOI: 10.1007/s11274-024-04012-z. View

19.

Mayendraraj A, Rosenkilde M, Gasbjerg L . GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation. Peptides. 2022; 151:170749. DOI: 10.1016/j.peptides.2022.170749. View

20.

Chimerel C, Emery E, Summers D, Keyser U, Gribble F, Reimann F . Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. 2014; 9(4):1202-8. PMC: 4308618. DOI: 10.1016/j.celrep.2014.10.032. View